UC Berkeley, UCSF & Stanford Labs Test Psilocybin Replicability

Neuroscientists across five laboratories at three Bay Area research institutions—UC Berkeley, UCSF, and Stanford University—have published a landmark multi-institutional replication study in the Nov. 2, 2026 issue of Nature Neuroscience, reporting that while a single 2 milligrams-per-kilogram dose of psilocybin produced consistent acute effects in mice after 10 minutes, pooled data showed no lasting behavioral changes 24 hours later, according to Berkeley News writer Robert Sanders.

Five-Lab Bay Area Consortium Tests Reproducibility in Psychedelic Science

Proposed by Stanford neuroscientist Robert Malenka, the four-year project launched in 2022 after a year of federal regulatory approvals and was funded by an anonymous donor to counter publication bias. The five participating labs included UC Berkeley professor of neuroscience Stephan Lammel, UC Berkeley assistant professor of molecular and cell biology Andrea Gomez (a member of the Laguna Pueblo tribe), Berkeley doctoral student and co-first author Odilia Lu, UCSF psychiatrist Vikaas Sohal, UCSF researcher Mazen Kheirbek, and Stanford researcher Boris Heifets:

• Acute 10-Minute Effects vs. 24-Hour Baseline: Across all five laboratories, mice injected with 2 mg/kg of psilocybin exhibited universal head twitching, heightened anxiety, avoidance of open spaces, and a decrease in the expression of fear 10 minutes after injection. However, 24 hours after a single dose, pooled results showed no replicable reduction in anxiety or depression-like behaviors (despite two labs seeing an effect in one of two swimming assays) and no reopening of the critical period for social reward learning.
• Building Reproducibility Into Basic Science: Noting National Institutes of Health Director Jay Bhattacharya's recent Science editorial on independent replication, Lammel, Gomez, Lu, and Sohal emphasized that parallel multi-lab trials can separate robust neural-circuit effects from handler, vendor, enclosure, or time-of-day variability.

Point-of-Care Bone Density and AI Retinal Screening at the 2026 HEDIS Summit

In clinical preventive medicine, the Castro Valley Forum reported that Plantation, Florida-based BeamMed Inc. (contact Gilad Zamir, 800-769-6808) is showcasing two point-of-care screening devices at the HEDIS & Quality Improvement Summit 2026 from Nov. 3 through Nov. 5, 2026 at the Baltimore Marriott Inner Harbor at Camden Yards: the radiation-free Sunlight MiniOmni quantitative ultrasound bone density scanner for osteoporosis assessment and a handheld AI-powered fundus camera that delivers autonomous diabetic retinopathy screening results in less than 60 seconds.